Erratum: One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency (Genetics in Medicine (2021) 23(8) (1543–1550), (S1098360021050620), (10.1038/s41436-021-01156-3))

George A. Diaz, Simon A. Jones, Maurizio Scarpa, Karl Eugen Mengel, Roberto Giugliani, Nathalie Guffon, Isabela Batsu, Patricia A. Fraser, Jing Li, Qi Zhang, Catherine Ortemann-Renon

Research output: Contribution to journalComment/debate

Abstract

Correction to: Genetics in Medicine 2022; https://doi.org/10.1038/s41436-021-01156-3 In the article “One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency” by Diaz GA et al (Genet Med 2021;23:1543-1550), there were two typographical errors. In the “Exploratory efficacy, Spleen and liver volume” section, the mean baseline liver volume is incorrectly typed as 2.2 ± 0.7 MN; the correct value is 2.7 ± 0.7 MN. In the “Pharmacodynamics” section, the unit for the lyso-sphingomyelin normal value is incorrect in one place in the text; it is typed as (ULN 9.99 μg/mL and 181 μmol/L/hr) and it should be (ULN 9.99 μg/L and 181 μmol/L/hr).

Original languageEnglish
Pages (from-to)2209
Number of pages1
JournalGenetics in Medicine
Volume24
Issue number10
DOIs
StatePublished - Oct 2022

Fingerprint

Dive into the research topics of 'Erratum: One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency (Genetics in Medicine (2021) 23(8) (1543–1550), (S1098360021050620), (10.1038/s41436-021-01156-3))'. Together they form a unique fingerprint.

Cite this